Stand Up To Cancer - standuptocancer.orgThis is where the end of cancer begins
   Please leave this field empty

In The News

Share this:

Like this page on Facebook

Dream Team Leader Becomes President-Elect of AACR

Elizabeth M. Jaffee, MD, leader of the SU2C-Lustgarten Foundation Pancreatic Cancer Dream Team, has been elected president-elect of the American Association for Cancer Research, SU2C’s Scientific Partner. Dr. Jaffee, who is deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore; will become president of AACR one year from now. She is an internationally recognized expert in cancer immunology, with specific expertise in preclinical and early clinical development of immunotherapies for breast and pancreatic cancers. The Dream Team was launched in 2014 and is developing new treatments for pancreatic ductal adenocarcinoma (PDA), the most common form of cancer of the pancreas.

+ More

Colorectal Cancer Rates Rising Sharply Among Gen X and Millennials

A new study shows that colorectal cancer rates are rising sharply among young and middle-aged adults.

+ More

SU2C scientists probe patient response to cancer immunotherapy

In research supported by SU2C, F. Stephen Hodi, MD, of the Dana-Farber Cancer Institute and colleagues investigated whether a serumbiomarker could predict the response of patients receiving immune checkpoint inhibitors, a type of immunotherapy. This is very important to improving the utilization ofimmunotherapies. According to a paper published in a journal published by SU2C’s Scientific Partner, the American Association for Cancer Research, Hodi’s team found that serum levels of a protein called ANGPT2 predicted response to, and influenced the outcomes of,immune checkpoint inhibitors in patients with advanced melanoma.

+ More

Scientific Advisory Committee member, Dr. David Tuveson, named director of Cold Spring Harbor cancer

David Tuveson, MD, PhD, a leader in pancreatic cancer research, and member of SU2C’s Scientific Advisory Committee has been named the new director of CSHL’s cancer center, a National Cancer Institute (NCI)-designated research facility. In addition to his roles at Cold Spring Harbor Lab, where he is a professor, and as one of our SU2C scientific leaders, Tuveson is a clinician who treats pancreatic cancer patients at Memorial Sloan Kettering Cancer Center and is Director of Research for SU2C collaborator, the Lustgarten Foundation for Pancreatic Research.

+ More

SU2C scientist named a 2016 Giant of Cancer Care

Dr. Daniel Von Hoff, physician-in-chief and Distinguished Professor at the Translational Genomics Research Institute (TGen) at Mayo Clinic and leader of the SU2C-CRUK-Lustgarten Foundation Pancreatic Cancer Dream Team, was named a 2016 Giant of Cancer Care. This prestigious award honors the achievements of exceptional leaders in the field of oncology research and clinical practice.

+ More

Innovate Collaborate Accelerate